Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis

Chest

Volumn 141, Issue 3, 2012, Pages 661-673

  Mura, Marco ^a   Anraku, Masaki ^a   Yun, Zhihong ^a   McRae, Karen ^a   Liu, Mingyao ^a   Waddell, Thomas K ^a   Singer, Lianne G ^a   Granton, John T ^a   Keshavjee, Shaf ^a   De Perrot, Marc ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA SYNTHESIS; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REGULATORY NETWORK; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; LUNG FIBROSIS; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MYOFIBROBLAST; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION;

EID: 84857959672     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0449     Document Type: Article

References (45)

1. Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006;100(10): 1734-1741. (Pubitemid 44283761)
2. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746-752.
3. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007;131(3):650-656. (Pubitemid 46446853)
4. Fang A, Studer S, Kawut SM, et al;Lung Transplant Outcomes Group. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest. 2011; 139(4):782-787.
5. American Thoracic Society;European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277-304.
6. Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis-relation with the duration of the disease. Int J Cardiol. 2008;127(3):410-412. (Pubitemid 351885079)
7. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006;130(5):1481-1488. (Pubitemid 44786743)
8. Evers H, Liehs F, Harzbecker K, et al. Screening of pulmonary hypertension in chronic obstructive pulmonary disease and silicosis by discriminant functions. Eur Respir J. 1992; 5(4):444-451.
9. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003;30(11):2398-2405. (Pubitemid 37413900)
10. Pekdemir H, Camsari A, Akkus MN, Cicek D, Tuncer C, Yildirim Z. Impaired cardiac autonomic functions in patients with environmental asbestos exposure: a study of time domain heart rate variability. J Electrocardiol. 2003;36(3):195-203. (Pubitemid 37052325)
11. Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol. 2011;45(1):1-15.
12. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715-721. (Pubitemid 351194832)
13. Zisman DA, Karlamangla AS, Kawut SM, et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2008;133(3):640-645. (Pubitemid 351367371)
14. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006;173(7):744-750.
15. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 2007;82(3):342-350. (Pubitemid 46348935)
16. Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J. 2008;32(1):170-174.
17. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med. 2007;175(9):875-880. (Pubitemid 46684695)
18. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131(3):657-663. (Pubitemid 46446854)
19. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):285-292. (Pubitemid 43845404)
20. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. (Pubitemid 41528093)
21. Ashburner M, Ball CA, Blake JA, et al; The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25-29. (Pubitemid 30257031)
22. Cottin V, Le Pavec J, Prévot G, et al GERM "O" P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35(1) : 105-111.
23. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25(5):783-788. (Pubitemid 40667674)
24. Galiè N, Hoeper MM, Humbert M, et al;ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493-2537.
25. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34(4):888-894.
26. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S55-S66.
27. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1) : 92-99.
28. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW;Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-628.
29. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63(3):783-794.
30. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007; 132(3):998-1006.
31. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004;169(11) : 1203-1208. (Pubitemid 38680397)
32. Renzoni EA, Walsh DA, Salmon M, et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med. 2003;167(3):438-443. (Pubitemid 36216429)
33. Geraci MW, Gao B, Hoshikawa Y, Yeager ME, Tuder RM, Voelkel NF. Genomic approaches to research in pulmonary hypertension. Respir Res. 2001;2(4):210-215. (Pubitemid 34187928)
34. Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profi brotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2005;2(9):e251.
35. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5(4):e93.
36. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006;3(4) : 383-388. (Pubitemid 43845417)
37. Ivy D, McMurtry IF, Yanagisawa M, et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2001;280(5):L1040-L1048.
38. Ivy DD, Yanagisawa M, Gariepy CE, Gebb SA, Colvin KL, McMurtry IF. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol. 2002;282(4):L703-L712. (Pubitemid 34665585)
39. Zeng X, Zhu Y, Lu H. NBP is the p53 homolog p63. Carcinogenesis. 2001;22(2):215-219.
40. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655-1665.
41. He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1039-L1049. (Pubitemid 47084848)
42. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol. 2003;170(6):3233-3242. (Pubitemid 36302201)
43. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54(s uppl 1):S10-S19.
44. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med. 2008;177(1):114-120.
45. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(6):659-664. (Pubitemid 44395333)